Literature DB >> 29159001

A Unique Case of Acute Cerebral Venous Sinus Thrombosis Secondary to Primary Varicella Zoster Virus Infection.

Syed F Imam1, Omair Ul Haq Lodhi2, Zainab Fatima3, Saneeya Nasim4, Waseem T Malik4, Muhammad Sabih Saleem3.   

Abstract

Primary varicella zoster virus (VZV) infection, predominantly in the pediatric population, presents with pyrexia and a classic pruritic vesicular rash. In adults, although less common, it is more severe and linked to more complications. Neurological complications, which account for less than 1% of all VZV complications, include meningitis, encephalitis, arterial vasculopathy, and venous thrombosis. We present a case of a 39-year-old male who developed extensive cerebral venous sinus thrombosis following primary VZV infection. Venous thrombosis in VZV has been suggested to be caused by autoantibodies against protein S, pre-existing hypercoagulability, or endothelial damage. The patient was acutely managed using intravenous acyclovir and heparin. Long-term anticoagulation therapy with warfarin was continued after discharge. We concluded that clinicians should be aware of the rare complications of this common pathology so that a timely diagnosis can be made, followed by prompt management. Further studies need to be done to better understand acute cerebral venous sinus thrombosis secondary to VZV.

Entities:  

Keywords:  cerebral venous thrombosis; chickenpox; cvst; cvt; varicella; venous thrombosis; vzv

Year:  2017        PMID: 29159001      PMCID: PMC5690469          DOI: 10.7759/cureus.1693

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  6 in total

Review 1.  Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Gustavo Saposnik; Fernando Barinagarrementeria; Robert D Brown; Cheryl D Bushnell; Brett Cucchiara; Mary Cushman; Gabrielle deVeber; Jose M Ferro; Fong Y Tsai
Journal:  Stroke       Date:  2011-02-03       Impact factor: 7.914

2.  Cerebral venous sinus thrombosis: association with primary varicella zoster virus infection.

Authors:  Shaista Anwar Siddiqi; Sadia Nishat; Durreshahwar Kanwar; Farheen Ali; Muhammad Azeemuddin; Mohammad Wasay
Journal:  J Stroke Cerebrovasc Dis       Date:  2012-06-08       Impact factor: 2.136

3.  The varicella-autoantibody syndrome.

Authors:  C Josephson; R Nuss; L Jacobson; M R Hacker; J Murphy; A Weinberg; M J Manco-Johnson
Journal:  Pediatr Res       Date:  2001-09       Impact factor: 3.756

4.  Headache as the only neurological sign of cerebral venous thrombosis: a series of 17 cases.

Authors:  R Cumurciuc; I Crassard; M Sarov; D Valade; M G Bousser
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

Review 5.  Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Authors:  Niklaus H Mueller; Donald H Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

6.  Unseen face of varicella-zoster infection in adults.

Authors:  Gunchan Paul; Birinder S Paul; Gagandeep Singh
Journal:  Indian J Crit Care Med       Date:  2016-12
  6 in total
  3 in total

1.  First case report of pulmonary embolism with Zoster Sine Herpete.

Authors:  Syeda Sahra; Abdullah Jahangir; Mishelle Centeno Gavica; Neville Mobarakai; Ahmad Jahangir
Journal:  Respir Med Case Rep       Date:  2021-06-24

Review 2.  Chronic Headache and Cerebral Venous Sinus Thrombosis Due to Varicella Zoster Virus Infection: A Case Report and Review of the Literature.

Authors:  Laith Alamlih; Mohammad Abdulgayoom; Suresh N Menik Arachchige; Mohammed Hamza Shah; Muhammad Zahid
Journal:  Am J Case Rep       Date:  2021-03-17

3.  Case Study of Pediatric Cerebral Sinus Venous Thrombosis Center of a Low Middle-Income Country.

Authors:  Bushra Moiz; Ronika Devi Ukrani; Aiman Arif; Inaara Akbar; Muhammed Wahhaab Sadiq; Sadaf Altaf
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.